1. Second allogeneic stem cell transplantation in acute leukemia patients: single-centre experience
- Author
-
Nurgül Özcan, Merih Kızıl Çakar, Mehmet Bakırtaş, Bahar Uncu Ulu, Tuğçe Nur Yiğenoğlu, Fevzi Altuntaş, Dicle İskender, Semih Başcı, and Mehmet Sinan Dal
- Subjects
allogeneic stem cell transplant ,relapse ,medicine.medical_specialty ,Poor prognosis ,Acute leukemia ,lcsh:R5-920 ,business.industry ,Complete remission ,Treatment options ,Transplantation ,Clinical trial ,Single centre ,surgical procedures, operative ,immune system diseases ,Internal medicine ,hemic and lymphatic diseases ,Medicine ,acute myeloid leukaemia ,Stem cell ,business ,lcsh:Medicine (General) ,therapeutics ,human activities - Abstract
Acute leukaemia patients who relapse after the first allogeneic stem cell transplantation (Allo-SCT) have a poor prognosis. Participating in clinical trials is the best option for these patients. If patients cannot participate in clinical trials, as the treatment options are limited, the second allo-SCT constitutes the potential curative treatment option. The data of acute leukaemia patients who underwent second allo-SCT because of relapsed/refractory disease after the first allo-SCT at our centre between December 2009 and February 2019 were analyzed retrospectively. Three hundred nineteen acute leukaemia patients were performed allo-SCT at our centre. 20 of these 319 acute leukaemia patients relapsed after first allo-SCT and underwent second allo-SCT. 10 AML patients and 10 ALL patients were included in the study. After second allo-SCT overall survival (OS) was 26.1±10.8 weeks, and progression-free survival (PFS) was 19.9±8.6 weeks. If the patients cannot participate in clinical trials, second allo-SCT should be considered for patients with late (≥12 months) relapses after the first allo-SCT. If possible, haploidentical donors should be selected for second allo-SCT and patients should be in complete remission before the transplant.
- Published
- 2020